Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2. The new ...

Attendance feels lighter and the booths are notably more subdued, but galleries across the board report strong blue-chip placements.

This piece was updated to add an explanation about the changes to the sections around driver’s licenses. On Trans Day of Visibility, an Ohio Republican has introduced a new bill that would limit trans ...